Rating Scales

Parkinson's Disease

Volumn , Issue , 2004, Pages 663-676

  Shannon, Kathleen M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38349163486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-61     Document Type: Chapter

References (44)

1. Schwab, R. S. and Chafetz, M. E., Kemadrin in the treatment of parkinsonism, Neurol Clin, 5, 273–277, 1955.
2. Strang, R. R., Experiences with cogentin in the treatment of parkinsonism, Acta Neurol. Scand., 41, 413–418, 1965.
3. Webster, D. D., Critical analysis of the disability in Parkinson’s disease, Mod. Treat., 5, 257–258, 1968.
4. Geminiani, G., Cesana, B. M., Tamma, F., Contri, P., Pacchetti, C., Carella, F., Piolti, R., Martignoni, E., Gio-vannini, P., Girotti, F., and et al., Interobserver reliability between neurologists in training of Parkinson’s disease rating scales. A multicenter study, Mov. Disord., 6 (4), 330–5, 1991.
5. Ginanneschi, A., Degl’Innocenti, F., Magnolfi, S., Mau-rello, M. T., Catarzi, L., Marini, P., and Amaducci, L., Evaluation of Parkinson’s disease: Reliability of three rating scales, Neuroepidemiology, 7 (1), 38–41, 1988.
6. Martinez-Martin, P., Gil-Nagel, A., Gracia, L. M., Gomez, J. B., Martinez-Sarries, J., and Bermejo, F., Unified Parkinson’s Disease Rating Scale characteristics and structure, The Cooperative Multicentric Group, Mov. Disord., 9 (1), 76–83, 1994.
7. Ramaker, C., Marinus, J., Stiggelbout, A. M., and Van Hilten, B. J., Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease, Mov. Disord., 17 (5), 867–76, 2002.
8. Hoehn, M. M. and Yahr, M. D., Parkinsonism: Onset, progression and mortality, Neurology, 17, 427–442, 1967.
9. Lang, A. E. and Fahn, S., Assessment of Parkinson’s disease, in Quantification of Neurologic Deficit, Munsat, T. L. Butterworth-Heineman, Stoneham, M. A.,1989.
10. Canter, C. J., de la Torre, R., and Mier, M., A method of evaluating disability in patients with Parkinson’s dis-ease, J. Nerv. Ment. Dis., 133, 143–147, 1961.
11. Henderson, B. T., Kenny, B. G., Hitchcock, E. R., Hughes, R. C., and Clough, C. G., A comparative eval-uation of clinical rating scales and quantitative measure-ments in assessment pre and post striatal implantation of human foetal mesencephalon in Parkinson’s disease, Acta Neurochir. Suppl. (Wien), 52, 48–50, 1991.
12. Martinez-Martin, P., Carrasco de la Pena J. L., Ramo, C., Antiguedad, A. R., and Bermejo, F., [Inter-observer reproducibility of qualitative scales in Parkinson disease (I)], Arch Neurobiol. (Madr), 50 (5), 309–14, 1987.
13. Lieberman, A., Dziatolowki, M., Gopinathan, G., and et al., Evaluation of Parkinson’s disease, in Ergot Com-pounds and Brain Function: Neuroendocrine and Neu-ropsychiatric Aspects, Goldstein, M., Raven, New York, 1980.
14. Treciokas, L. J., Ansel, R. D., and Markham, C. H., One to two year treatment of Parkinson’s disease with levodopa, Calif. Med., 114 (5), 7–14, 1971.
15. Parkes, J. D., Zilka, K. J., Calver, D. M., and Knill-Jones, R. P., Controlled trial of amantadine hydrochlo-ride in Parkinson’s disease, Lancet, 1, 259–262, 1970.
16. Montgomery, G. K., Reynolds, N. C., Jr., and Warren, R. M., Qualitative assessment of Parkinson’s disease: Study of reliability and data reduction with an abbrevi-ated Columbia Scale, Clin. Neuropharmacol., 8 (1), 83–92, 1985.
17. Fahn, S., Elton, R. I., and Members of the UPDRS Development Committee, The Unified Parkinson’s Dis-ease Rating Scale, in Recent Developments in Parkin-son’s Disease, Fahn, S., Marsden, C. D., Calne, D. B., and Goldstein, M. Macmillan Healthcare Information, Florham Park, pp. 153–163, 293–304, 1987.
18. Diamond, S. G. and Markham, C. H., A double-blind comparison of levodopa, madopar and sinemet in Par-kinson’s disease, Ann. Neurol., 3, 267–272, 1978.
19. The Unified Parkinson’s Disease Rating Scale (UPDRS): Status and recommendations, Mov. Disord., 18 (7), 738–750, 2003.
20. Louis, E. D., Lynch, T., Marder, K., and Fahn, S., Reli-ability of patient completion of the historical section of the Unified Parkinson’s Disease Rating Scale, Mov. Dis-ord., 11 (2), 185–92, 1996.
21. Martinez-Martin, P., Fontan, C., Frades Payo, B., and Petidier, R., Parkinson’s disease: Quantification of dis-ability based on the Unified Parkinson’s Disease Rating Scale, Neurologia, 15 (9), 382–7, 2000.
22. Wilson, R. S., Schneider, J. A., Bienias, J. L., Evans, D. A., and Bennett, D. A., Parkinsonianlike signs and risk of incident Alzheimer disease in older persons, Arch Neurol., 60 (4), 539–44, 2003.
23. Wilson, R. S., Schneider, J. A., Beckett, L. A., Evans, D. A., and Bennett, D. A., Progression of gait disorder and rigidity and risk of death in older persons, Neurol-ogy, 58 (12), 1815–9, 2002.
24. Ballard, C., O’Brien, J., Swann, A., Neill, D., Lantos, P., Holmes, C., Burn, D., Ince, P., Perry, R., and McK-eith, I., One year follow-up of parkinsonism in dementia with Lewy bodies, Dement. Geriatr. Cogn. Disord., 11 (4), 219–22, 2000.
25. Bennett, D. A., Shannon, K. M., Beckett, L. A., Goetz, C. G., and Wilson, R. S., Metric properties of nurses’ ratings of parkinsonian signs with a modified Unified Parkinson’s Disease Rating Scale, Neurology, 49 (6), 1580–7, 1997.
26. Goetz, C. G., Stebbins, G. T., Chmura, T. A., Fahn, S., Klawans, H. L., and Marsden, C. D., Teaching tape for the motor section of the unified Parkinson’s disease rat-ing scale, Mov. Disord., 10 (3), 263–6, 1995.
27. Mitchell, S. L., Harper, D. W., Lau, A., and Bhalla, R., Patterns of outcome measurement in Parkinson’s disease clinical trials, Neuroepidemiology, 19 (2), 100–8, 2000.
28. Morrish, P. K., Sawle, G. V., and Brooks, D. J., An [18F]dopa-PET and clinical study of the rate of progres-sion in Parkinson’s disease, Brain, 119 (Pt. 2), 585–91, 1996.
29. Seibyl, J. P., Marek, K., Sheff, K., Zoghbi, S., Baldwin, R. M., Charney, D. S., van Dyck, C. H., and Innis, R. B., Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy sub-jects and Parkinson’s patients, J. Nucl. Med., 39 (9), 1500–8, 1998.
30. Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., and et al., Variable expression of Parkin-son’s disease: A base-line analysis of the DATATOP cohort. The Parkinson Study Group, Neurology, 40 (10), 1529–34, 1990.
31. Stebbins, G. T. and Goetz, C. G., Factor structure of the Unified Parkinson’s Disease Rating Scale: Motor Exam-ination section, Mov. Disord., 13 (4), 633–6, 1998.
32. Stebbins, G. T., Goetz, C. G., Lang, A. E., and Cubo, E., Factor analysis of the motor section of the unified Parkinson’s disease rating scale during the off-state, Mov. Disord., 14 (4), 585–9, 1999.
33. Hariz, G. M., Lindberg, M., and Bergenheim, A. T., Impact of thalamic deep brain stimulation on disability and health-related quality of life in patients with essen-tial tremor, J. Neurol. Neurosurg. Psychiatry, 72 (1), 47–52, 2002.
34. Vieregge, P., Stolze, H., Klein, C., and Heberlein, I., Gait quantitation in Parkinson’s disease—locomotor disability and correlation to clinical rating scales, J. Neural. Transm., 104 (2-3), 237–48, 1997.
35. Kieburtz, K., Designing neuroprotection trials in Parkin-son’s disease, Ann. Neurol., 53 Suppl. 3, S100–7; dis-cussion S107-9, 2003.
36. Marras, C. and Lang, A. E., Measuring motor compli-cations in clinical trials for early Parkinson’s disease, J. Neurol. Neurosurg. Psychiatry, 74 (2), 143–6, 2003.
37. Goetz, C. G., Stebbins, G. T., Blasucci, L. M., and Grobman, M. S., Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson’s disease, Mov. Disord., 12 (6), 1039–41, 1997.
38. Larsen, T. A., Calne, S., and Calne, D. B., Assessment of Parkinson’s disease, Clin. Neuropharmacol., 7 (2), 165–9, 1984.
39. Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., and Watts, R., Core assessment program for intracerebral transplantations (CAPIT), Mov. Disord., 7 (1), 2–13, 1992.
40. Goetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., Ahlskog, J. E., and Dorflinger, E. E., Utility of an objective dyskinesia rating scale for Parkinson’s disease: Inter-and intrarater reliability assessment, Mov. Disord., 9 (4), 390–4, 1994.
41. Evaluation of dyskinesias in a pilot, randomized, pla-cebo-controlled trial of remacemide in advanced Parkin-son disease, Arch Neurol., 58 (10), 1660–8, 2001.
42. Hagell, P. and Widner, H., Clinical rating of dyskinesias in Parkinson’s disease: Use and reliability of a new rating scale, Mov. Disord., 14 (3), 448–55, 1999.
43. Defer, G. L., Widner, H., Marie, R. M., Remy, P., and Levivier, M., Core assessment program for surgical interventional therapies in Parkinson’s disease (CAP-SIT-PD), Mov. Disord., 14 (4), 572–84, 1999.
44. Stowe, R. L., Wheatley, K., Clarke, C. E., Ives, N. J., Hills, R. K., Williams, A. C., Daniels, J. P., and Gray, R., Surgery for Parkinson’s disease: Lack of reliable clin-ical trial evidence, J. Neurol. Neurosurg. Psychiatry, 74 (4), 519–21, 2003.